Report ID: SQMIG35H2037
Report ID:
SQMIG35H2037 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
65 |
Figures:
64
In Feb 2021, Dextenza, a product by Ocular Therapeutix was made available in the market. This product enables the course of steroid therapy possible just with a single installation of intracanalicular device.
In June 2020, the collaboration agreement between Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. has been extended to include innovative drug delivery techniques in ophthalmology.
Key Market Trends
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONOphthalmic Disease Therapeutics Market size was valued at USD 31.6 billion in 2019 and is poised to grow from USD 33.5 billion in 2023 to USD 53.8 billion by 2031, growing at a CAGR of 6.10% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2037